New hope for brain cancer: triple attack shows promise in early trial
NCT ID NCT03405792
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 34 times
Summary
This study tests whether adding the immunotherapy drug pembrolizumab to standard treatment (chemotherapy plus a device that sends electric fields to the brain) can help people with newly diagnosed glioblastoma, an aggressive brain cancer. About 40 adults with good physical function are participating. The main goal is to see if this combination delays cancer growth or death compared to past results.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Florida Health
Gainesville, Florida, 32610, United States
Conditions
Explore the condition pages connected to this study.